RE:RE:Mexicowhippet wrote:
Hey cheeseguy... re: Mexico, my understanding is Andre is in Mexico to sign deal. The documents we received were prepared relating to FY 2017 (March 31st). Since then, we had the financing, evolution in discussions relating to contracts, more R&D re: cardiovascular development and so on.
Management expectations were Revenues for FY2017 about 2.3M (in line with expectations), and working toward FY 2018... with expected Revenus 6.6M +.... which would then give a small profit, and would cover all expenses.... if all comes according to plans.... And for FY2018, so far i dont see any reason they wont achieve what they said they would do.
There will be some nervous shareholders..... that's fine..... it's a penny stock ....
what is also iteresting is the fact that the client (Mexico??) , wants to increase the number of tests to patients (clients).... If that one client 2X last year numbers, we will be over 2/3 the target for next year....
And that is without surprises..... which i think we will get this year.
Also, what i find interesting is the volume in other countries.... Looks like the tersting period is over and some of those surprises i hope for .... are gonna come from there.
As far as US listing, WE ARE OFF THE PINK SHEET BOARD. We are still OTC, and a MarketMaker should be hired next time Andre goes to the US....
R&D is still an important expense account. Most probably Cardiovascular.... would love to see the results so far.
We always want to see more and get rich overnight. but in my opinion, these FY2017 results are in line and pave the way for a great FY2018. They have contracts coming, strong cash position and AI technology with 98% efficiency results.
And at .14 you cant be wrong.
just my 2cents worth.
Have a good day.
whippet
Hey Whip it would be nice to know ...they spent over a million on R&D last year alone my guess is they are pushing hard to add something else with our AI platform like Cardio...exciting times forsure for this little gem of a company...
Later
Bob